Results 161 to 170 of about 10,303 (224)

Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults. [PDF]

Front Immunol
Koram KA, Walker KA, Orizu B, Marrero I, Boyer J, Yang S, Broderick KE, Kusi KA, Kyei-Baafour E, Ofori EA, Pobee A, Adu-Amankwah S, Amoakoh-Coleman M, Amoakoh HB, Abuaku B, Badji E, Ntiri M, Quaye L, Morrow MP, Sylvester AJ, Reuschel EL, Gillespie E, Liebowitz D, Humeau LM.   +23 more
europepmc   +1 more source

Detection of Immunoglobulin G and/or IgM antibodies specific for Lassa virus among HIV patients in the Northwestern region of Cameroon. [PDF]

Virol J
Abongwa LE, Njefi K, Ngum NH, Rogeson T, Ahmed M, Ajayi OI, Djoufack GD, Eromon P, Ugwu C, Folarin O, Happi C.   +10 more
europepmc   +1 more source

The Lassa Virus Stable Signal Peptide Undergoes a Conformational Change to Aid Viral Fusion. [PDF]

Chemistry
Collins SD, Jiang L, Liu Y, Lee J.
europepmc   +1 more source

Expansion of myeloid suppressor cells and suppression of Lassa virus-specific T cells during fatal Lassa fever. [PDF]

PLoS Pathog
Lafoux B, Fourcaud G, Hortion J, Soyer L, Journeaux A, Germain C, Reynard S, Cousseau H, Larignon C, Pietrosemoli N, Croze S, Lachuer J, Perthame E, Baize S.   +13 more
europepmc   +1 more source

Pathological Insights into Lassa Virus-Induced Vestibular Dysfunction in Mice: Histopathological Analysis of the Inner Ear Vestibular Apparatus. [PDF]

J Infect Dis
Suzuki T, Saito MH, Lin N, Tamura A, Yun N, Koma T, Maruyama J, Paessler S, Makishima T.   +8 more
europepmc   +1 more source

Coadministration of ribavirin and arenaviral entry inhibitor LHF-535 enhances antiviral benefit against authentic lassa virus. [PDF]

Virol Sin
Peng C, Hu J, Bai Y, Wu W, Mao W, Liu Y, Wan Y, Zhang L, Li W, Tian T, Liu T, Wang Y, Liang M, Han J, Yuan Z, Li J, Shan C, Deng F, Wang W.   +18 more
europepmc   +1 more source

A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs. [PDF]

NPJ Vaccines
Carey BD, Yu S, Geiger J, Ye C, Huzella LM, Reeder RJ, Mehta M, Hirsch S, Bernbaum R, Cubitt B, Pahar B, Anthony SM, Marketon A, Bernbaum JG, Tran JP, Crozier I, Martínez-Sobrido L, Worwa G, de la Torre JC, Kuhn JH.   +19 more
europepmc   +1 more source

Licoisoflavone B and glabridin from Glycyrrhiza glabra as potent nucleoprotein antagonists of Lassa virus: insights from molecular docking, dynamics simulation, PCA, and DFT studies. [PDF]

J Genet Eng Biotechnol
Faisal Ahmed S, Masudur Rahman Munna M, Hossain Ahmed M, Mostafizur Rahman M, Islam M, Bristy EM.   +5 more
europepmc   +1 more source

Report of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa virus disease and vaccines. [PDF]

Vaccine
Reed NS, Brewer CC, Akintunde G, Blackie FF, Charles L, Fast P, Lambert PH, Okogbenin S, Paessler S, Pinschewer DD, Top KA, Black SB, Dekker CL.   +12 more
europepmc   +1 more source

Identification of a macrocyclic compound targeting the lassa virus polymerase. [PDF]

Antiviral Res
Aida-Ficken V, Kelly JA, Chatterjee P, Jenks MH, McMullan LK, Albariño CG, Montgomery JM, Seley-Radtke KL, Spiropoulou CF, Flint M.   +9 more
europepmc   +1 more source